Newsbenzinga
Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual Meeting
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…